Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:56:07.113Z.
Calculation as of: 2026-10-06T14:56:07.113Z.
Quote observation: 2026-10-06T14:54:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dd458a7b7530169a13c79e175a6610edc18df904cb2af71895118b3708428af2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Boundless Bio, Inc.
Market Cap
$57.54M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Boundless Bio, Inc. (BOLD) | $57.54M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.49M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A |
| Aldeyra The (ALDX)vs › | $56.64M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $58.96M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $59.23M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.51M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $55.14M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.30M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $53.81M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
